Disulfiramlike Mushroom Toxicity

Back

Practice Essentials

Edible wild mushrooms often are gathered by foragers and prized for their taste. Occasionally, toxic mushrooms are mistaken for edible species, and human poisoning occurs. In addition, some food aficionados around the globe will intentionally eat certain mushrooms, despite their content of known toxins. For example, Coprinus atramentarius contains the heat-stable toxin coprine, which only causes toxicity when ethanol is consumed after the mushroom. Because victims of mushroom poisoning will most commonly seek initial medical care in emergency departments, it is important that emergency physicians be familiar with the diverse signs and symptoms of mushroom toxicity.

Coprinus atramentarius

C atramentarius, a member of Coprinaceae or inky cap family, is known familiarly as alcohol inky or inky cap. This mushroom is found particularly during autumn months in urban regions and along roadsides throughout the United States. Its cap is gray-brown, egg-shaped, smooth, and 2-3 inches in width. These mushrooms deliquesce, with gill tissue autodigesting to dark inky liquid after picking and with maturation.[1]

Other coprine-containing mushrooms

Other Coprinus mushrooms that contain coprine include C insignisC quadrifidus, and C variegatus. Some Coprinus mushrooms generally are not toxic, such as C comatus (ie, shaggy mane, lawyer's wig), which is sought for its asparagus-like qualities.

Clitocybe clavipes

Clitocybe clavipes, of the family Tricholomataceae, is also associated with disulfiramlike reactions. However, coprine has not been identified in this species. C clavipes tends to grow in coniferous or mixed woods; it fruits in late autumn or winter. Its cap is gray-brown, mostly flat, and 1-3 inches in width. Its gill extends down a stem that is club shaped and thickened near the base. C clavipes is commonly called fat-footed clitocybe or clubfoot funnel cap.

Lepiota aspera

Lepiota aspera, commonly known as freckled dapperling, has also been associated with disulfiramlike reactions.[2]  It has an orangish brown to pinkish brown cap and white gills.  The cause of the disulfiramlike reaction is unknown.

Pathophysiology

Coprinus atramentarius contains coprine (N5-1-hydroxycyclopropyl-L-glutamine), a protoxin without intrinsic toxicity. Coprine is metabolized to 1-aminocyclopropanol, which inhibits the enzyme aldehyde dehydrogenase (ALDH). ALDH catalyzes conversion of acetaldehyde to acetic acid.

Inhibition of ALDH produces a clinical syndrome similar to disulfiram (Antabuse) alcohol reaction. Disulfiram has been widely used in the manufacture of rubber since the 1800s. In 1937, an American chemical plant physician noted that employees exposed to disulfiram in the workplace developed a constellation of symptoms after drinking ethanol. These included flushing, headache, nausea, palpitations, and dyspnea, and the symptoms were severe enough to promote abstinence from ethanol. In later years, the basis for this effect, the disulfiram-mediated inhibition of ALDH, was discovered. Ethanol is primarily metabolized by alcohol dehydrogenase to acetaldehyde, which is then metabolized by ALDH to acetate and carbon dioxide. Accumulation of acetaldehyde leads to the clinical manifestations of the disulfiram-ethanol interaction.

Disulfiram has been widely used in the treatment of alcohol dependence,[3]  although its benefits are the subject of controversy.[4]  It has also been used more recently in the management of cocaine dependence.[5, 6]

After ingestion of coprine-containing mushrooms, ALDH is irreversibly inhibited and consumption of ethanol results in acetaldehyde accumulation. This inhibition of ALDH takes at least 30 minutes, which is the time required to metabolize inactive coprine to active 1-aminocyclopropanol. Therefore, small volumes of ethanol ingested concomitantly with mushrooms may not cause toxicity. Enzyme inhibition generally persists for approximately 72 hours but animal studies suggest it may continue for up to 6 days.[7] Ingestion of ethanol up to 3 days after mushroom ingestion may produce acetaldehyde toxicity.

Unlike disulfiram, coprine does not appear to inhibit dopamine beta-hydroxylase, the enzyme that hydroxylates dopamine to form norepinephrine within storage vesicles of presynaptic neurons. In experimental models, rats exposed to coprine are capable of eliciting a tachycardic response to ethanol challenge; those exposed to disulfiram are not capable of eliciting this response (presumably due to inhibition of dopamine beta-hydroxylase[8] ). Whether a similar response occurs in humans is unknown.

Epidemiology

According to the American Association of Poison Control Centers' National Poison Data System (NPDS), coprine-containing mushrooms account for a minority of reported mushroom exposures. Of 5781 mushroom exposures reported in 2017, coprine-containing mushrooms accounted for only 10 case mentions, with 9 single exposures. Five of those patients were treated in a health care facility but no major outcomes or deaths were reported.[9]

No adequate database exists to determine frequency of coprine exposure or toxicity internationally, although some sources suggest a 1-3% frequency of all reported mushroom poisonings.

Since ethanol ingestion is necessary for toxicity, children generally are not affected.

Prognosis

The prognosis is excellent. With appropriate supportive care, morbidity associated with coprine-induced acetaldehyde toxicity is minimal and recovery is generally complete.

Mortality and morbidity rates due to secondary effects, such as dehydration or cardiovascular collapse, are unknown. Esophageal rupture attributed to vomiting following co-ingestion of ethanol and coprine-containing mushrooms has been reported, but such cases appear to be infrequent[10] .

Complications from prolonged emesis include the following:

Patient Education

Educate patients about the risks of eating unidentified wild mushrooms. If toxic mushrooms were intentionally eaten, educate patients about coprine toxicity with ethanol ingestion.

Patients should be advised to avoid alcohol for approximately 1 week.

For patient education information, see the First Aid and Injuries Center, as well as Food Poisoning and Activated Charcoal.

History

Obtaining a history of mushroom ingestion is critical in evaluating a patient with a disulfiramlike exposure. Raw and cooked mushrooms as well as the cooking water are capable of producing toxicity through aldehyde dehydrogenase (ALDH) inhibition. As long as the ethanol is ingested after the mushroom, symptoms can begin within minutes or be delayed for several hours after ethanol ingestion. Note that ethanol use may be unintentional (eg, cough syrup).

Patients may relate symptoms to ethanol, not mushrooms. Ascertaining if other species of wild mushrooms were ingested concomitantly and the approximate elapsed time since ingestion is important.

Signs and symptoms of disulfiramlike exposure include[11] :

The duration of symptoms is generally brief, around 30 min, but occasionally can last up to 24 h.

Physical Examination

Findings on physical examination may include the following:

Hypotension is less common than with disulfiram and coma is uncommon to rare.[11]

Laboratory Studies

The extent of diagnostic testing is guided by the patient's clinical presentation. Appropriate laboratory studies may include the following:

Other Tests

Obtaining an electrocardiogram (ECG) in patients with chest pain would be prudent. One case report described a 22-year-old chronic alcoholic male on disulfiram who consumed alcohol and then developed anginal symptoms.[12] ECG changes were consistent with an inferior wall myocardial infarction (MI). He underwent coronary angiography, which revealed clean vessels, and his MI was attributed to vasospasm.

A mycologist may positively identify the mushroom species involved. However, unlike identification of Amanita phalloides, positive identification of coprine-containing mushrooms rarely contributes to diagnosis or alters management.

Prehospital Care

Supportive care and parenteral rehydration are essential.

Emergency Department Care

Symptomatic treatment (eg, antiemetics) and supportive maneuvers are mainstays of medical management. Provide intravenous fluids if gastrointestinal effects have not abated.

Hypotension generally responds to volume expansion with normal saline. Patients with severe hypotension may require vasopressor agents once volume restoration is ensured. Direct-acting vasopressors (eg, norepinephrine) are preferred over indirect-acting agents (eg, dopamine). This recommendation derives from the known pharmacology of disulfiram, which inhibits dopamine beta-hydroxylase, thereby depleting presynaptic catecholamines.

Activated charcoal is unlikely to be of benefit if patient already has symptoms.

Fomepizole (4-methylpyrazole) could theoretically be of benefit by blocking alcohol dehydrogenase and formation of acetaldehyde. Its use in the treatment of methanol and ethylene glycol poisoning is well established.[13, 14] Fomepizole is currently very expensive, and its use is not established in this clinical setting.

Histamine-2 blockers (cimetidine is best studied) reduce the severity of flush and hypotension in Asian patients who experience these effects following ethanol ingestion. The Asian flush is due in part to a relative deficiency of aldehyde dehydrogenase.

Antiemetics with alpha-adrenergic blocking properties (eg, aliphatic and piperidine phenothiazines) should be avoided.

Consultations

Consultation with a regional Poison Control Center, toxicologist, or mycologist is recommended.

Medication Summary

The goals of pharmacotherapy are to reduce morbidity, to prevent complications, and to neutralize effects of the toxin.

Activated charcoal (Actidose-Aqua, Insta-Char, Liqui-Char)

Clinical Context:  Most useful if administered within 1 h of ingestion. Repeat doses may be used, especially with ingestion of sustained release agents. Limited outcome studies exist, especially when administration is more than 1 h after ingestion.

Administration of charcoal by itself (in aqueous solution), as opposed to coadministration with a cathartic, is becoming the current practice standard because no studies have shown benefit from cathartics and, while most drugs and toxins are adsorbed within 30-90 min, laxatives take hours to work. Dangerous fluid and electrolyte shifts have occurred when cathartics are used in small children.

When ingested dose is known, charcoal may be given at 10 times ingested dose of agent over 1 or 2 doses.

Class Summary

These agents are empirically used to minimize systemic adsorption of the toxin.

Metoclopramide (Reglan)

Clinical Context:  Prokinetic agent that increases GI motility and accelerates gastric emptying. Works as antiemetic by blocking dopamine receptors in chemoreceptor trigger zone of CNS.

Prochlorperazine (Compazine)

Clinical Context:  May relieve nausea and vomiting by blocking postsynaptic mesolimbic dopamine receptors through anticholinergic effects and depressing reticular activating system.

In addition to antiemetic effects, it has the advantage of augmenting hypoxic ventilatory response, acting as a respiratory stimulant at high altitude.

Class Summary

These agents are used to control nausea and vomiting.

Ranitidine (Zantac)

Clinical Context:  H2-receptor antagonist that may be a useful adjunct in reducing emesis volume.

Class Summary

H2-receptor antagonists are reversible competitive blockers of histamine at the H2 receptors, particularly those in the gastric parietal cells where they inhibit acid secretion. The H2-receptor antagonists are highly selective, do not affect the H1 receptors, and are not anticholinergic agents.

Ondansetron (Zofran)

Clinical Context:  Selective 5-HT3-receptor antagonist that blocks serotonin both peripherally and centrally. Indicated for nausea and vomiting due to radiation and/or chemotherapy, for postoperative nausea and vomiting, and for general symptomatic relief. While historically an expensive medication, recent availability of a generic form has removed cost as a consideration.

Class Summary

These agents are used to treat vomiting and symptomatic nausea resulting from radiation therapy and/or chemotherapy, for postoperative nausea and vomiting, and for general symptomatic relief.

Author

Stephen L Thornton, MD, Associate Clinical Professor, Department of Emergency Medicine (Medical Toxicology), University of Kansas Hospital; Medical Director, University of Kansas Hospital Poison Control Center; Staff Medical Toxicologist, Children’s Mercy Hospital

Disclosure: Nothing to disclose.

Specialty Editors

John T VanDeVoort, PharmD, Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

Disclosure: Nothing to disclose.

Chief Editor

Sage W Wiener, MD, Assistant Professor, Department of Emergency Medicine, State University of New York Downstate Medical Center; Director of Medical Toxicology, Department of Emergency Medicine, Kings County Hospital Center

Disclosure: Nothing to disclose.

Additional Contributors

B Zane Horowitz, MD, FACMT, Professor, Department of Emergency Medicine, Oregon Health and Sciences University School of Medicine; Medical Director, Oregon Poison Center; Medical Director, Alaska Poison Control System

Disclosure: Nothing to disclose.

C Crawford Mechem, MD, MS, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania School of Medicine; Emergency Medical Services Medical Director, Philadelphia Fire Department

Disclosure: Nothing to disclose.

Acknowledgements

Michael Hodgman, MD Assistant Clinical Professor of Medicine, Department of Emergency Medicine, Bassett Healthcare

Michael Hodgman, MD is a member of the following medical societies: American College of Medical Toxicology, American College of Physicians, Medical Society of the State of New York, and Wilderness Medical Society

Disclosure: Nothing to disclose.

References

  1. Kang Y, Kim H, Choi HT. Biochemical characterization of chitinase 2 expressed during the autolytic phase of the inky cap, Coprinellus congregatus. J Microbiol. 2013 Apr. 51(2):189-93. [View Abstract]
  2. Haberl B, Pfab R, Berndt S, Greifenhagen C, Zilker T. Case series: Alcohol intolerance with Coprine-like syndrome after consumption of the mushroom Lepiota aspera (Pers.:Fr.) Quél., 1886 (Freckled Dapperling). Clin Toxicol (Phila). 2011 Feb. 49 (2):113-4. [View Abstract]
  3. Mutschler J, Grosshans M, Soyka M, Rösner S. Current Findings and Mechanisms of Action of Disulfiram in the Treatment of Alcohol Dependence. Pharmacopsychiatry. 2016 Jul. 49 (4):137-41. [View Abstract]
  4. Skinner MD, Lahmek P, Pham H, Aubin HJ. Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014. 9 (2):e87366. [View Abstract]
  5. Malcolm R, Olive MF, Lechner W. The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opin Drug Saf. 2008 Jul. 7(4):459-72. [View Abstract]
  6. Garbutt JC. The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat. 2009 Jan. 36(1):S15-23; quiz S24-5. [View Abstract]
  7. Marchner H, Tottmar O. A comparative study on the effects of disulfiram, cyanamide and 1-aminocyclopropanol on the acetaldehyde metabolism in rats. Acta Pharmacol Toxicol (Copenh). 1978 Sep. 43 (3):219-32. [View Abstract]
  8. Carlsson A, Henning M, Lindberg P, Martinson P, Trolin G, Waldeck B, et al. On the disulfiram-like effect of coprine, the pharmacologically active principle of Coprinus atramentarius. Acta Pharmacol Toxicol (Copenh). 1978 Apr. 42 (4):292-7. [View Abstract]
  9. Gummin DD, Mowry JB, Spyker DA, Brooks DE, Osterthaler KM, Banner W. 2017 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 35th Annual Report. Clin Toxicol (Phila). 2018 Dec 21. 54 (10):1-203. [View Abstract]
  10. Meyer JH, Herlocher JE, Parisian J. Esophageal rupture after mushroom-alcohol ingestion. N Engl J Med. 1971 Dec 2. 285(23):1323. [View Abstract]
  11. White J, Weinstein SA, De Haro L, Bédry R, Schaper A, Rumack BH, et al. Mushroom poisoning: A proposed new clinical classification. Toxicon. 2019 Jan. 157:53-65. [View Abstract]
  12. Tayyareci Y, Acarel E. Acute myocardial infarction associated with disulfiram-alcohol interaction in a young man with normal coronary arteries. Turk Kardiyol Dern Ars. 2009. 37(1):48-50. [View Abstract]
  13. McMartin K, Jacobsen D, Hovda KE. Antidotes for poisoning by alcohols that form toxic metabolites. Br J Clin Pharmacol. 2016 Mar. 81 (3):505-15. [View Abstract]
  14. Thanacoody RH, Gilfillan C, Bradberry SM, Davies J, Jackson G, Vale AJ, et al. Management of poisoning with ethylene glycol and methanol in the UK: a prospective study conducted by the National Poisons Information Service (NPIS). Clin Toxicol (Phila). 2016. 54 (2):134-40. [View Abstract]
  15. Banys P. The clinical use of disulfiram (Antabuse): a review. J Psychoactive Drugs. 1988 Jul-Sep. 20(3):243-61. [View Abstract]
  16. Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med. 2005 Feb. 28(2):175-83. [View Abstract]
  17. Brent J, McMartin K, Phillips S, Aaron C, Kulig K; Methylpyrazole for Toxic Alcohols Study Group. Fomepizole for the treatment of methanol poisoning. N Engl J Med. 2001 Feb. 344(6):424-9. [View Abstract]
  18. Carlsson A, Henning M, Lindberg P, Martinson P, Trolin G, Waldeck B, et al. On the disulfiram-like effect of coprine, the pharmacologically active principle of Coprinus atramentarius. Acta Pharmacol Toxicol (Copenh). 1978 Apr. 42(4):292-7. [View Abstract]
  19. Christensen JK, Moller IW, Ronsted P, Angelo HR, Johansson B. Dose-effect relationship of disulfiram in human volunteers. I: Clinical studies. Pharmacol Toxicol. 1991 Mar. 68(3):163-5. [View Abstract]
  20. Hender E, May T, Beulke S. Poisoning due to eating fungi in Victoria. Aust Fam Physician. 2000 Oct. 29(10):1000-4. [View Abstract]
  21. Ho MP, Yo CH, Liu CM, Chen CL, Lee CC. Refractive hypotension in a patient with disulfiram-ethanol reaction. Am J Med Sci. 2007 Jan. 333(1):53-5. [View Abstract]
  22. Kunkel DB, Connor DA. Coprine-containing mushrooms. Spoerke DG, Rumack BH. Handbook of Mushroom Poisoning: Diagnosis and Treatment. CRC Press, LLC; 1994. 303-7.
  23. Michelot D. Poisoning by Coprinus atramentarius. Nat Toxins. 1992. 1(2):73-80. [View Abstract]
  24. Miller NS, Goodwin DW, Jones FC, Gabrielli WF, Pardo MP, Anand MM, et al. Antihistamine blockade of alcohol-induced flushing in orientals. J Stud Alcohol. 1988 Jan. 49(1):16-20. [View Abstract]
  25. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006 Jun. 26(3):290-302. [View Abstract]
  26. Wright C, Moore RD. Disulfiram treatment of alcoholism. Am J Med. 1990 Jun. 88(6):647-55. [View Abstract]
  27. Yilmaz A, Gursoy S, Varol O, Nur N, Ozyilkan E. Emergency room cases of mushroom poisoning. Saudi Med J. 2006 Jun. 27(6):858-61. [View Abstract]
  28. Bogenschutz MP, Bhatt S, Bohan J, Foster B, Romo P, Wilcox CE, et al. Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study. Am J Drug Alcohol Abuse. 2016 Sep. 42 (5):490-499. [View Abstract]
  29. Goedde HW, Agarwal DP, Harada S, Meier-Tackmann D, Ruofu D, Bienzle U, et al. Population genetic studies on aldehyde dehydrogenase isozyme deficiency and alcohol sensitivity. Am J Hum Genet. 1983 Jul. 35 (4):769-72. [View Abstract]